Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Mani

Showing results (81-90 of 169) with videos related to

Pageof 17
Sort By:
Digestive Diseases and Sciences|December 24, 2014
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infectionMaria Buti, Naoky Tsai, Joerg Petersen, et al.
JCI Insight|January 26, 2018
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitisRohit Loomba, Yevgeniy Gindin, Zhaoshi Jiang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 31, 2017
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosisTarik Asselah, Stefan Bourgeois, Stephen Pianko, et al.
Journal of Hepatology|June 11, 2018
Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipientsKosh Agarwal, Lluís Castells, Beat Müllhaupt, et al.
Journal of Lipid Research|July 14, 2022
Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patientsEric J Lawitz, Kelvin W Li, Edna Nyangau, et al.
Journal of Hepatology|December 3, 2014
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infectionKosh Agarwal, Scott K Fung, Tuan T Nguyen, et al.
Annals of Internal Medicine|November 4, 2014
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot studyAnu Osinusi, Anita Kohli, Miriam M Marti, et al.
Gastroenterology|August 7, 2015
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infectionGraham R Foster, Stephen Pianko, Ashley Brown, et al.
The New England Journal of Medicine|July 10, 2009
Raxibacumab for the treatment of inhalational anthraxThi-Sau Migone, G Mani Subramanian, John Zhong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2016
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL TrialsJason Grebely, Gregory J Dore, Stefan Zeuzem, et al.
Pageof 17

Showing results (81-90 of 169) with videos related to

Sort By:
Pageof 17
Digestive Diseases and Sciences|December 24, 2014
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infectionMaria Buti, Naoky Tsai, Joerg Petersen, et al.
JCI Insight|January 26, 2018
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitisRohit Loomba, Yevgeniy Gindin, Zhaoshi Jiang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 31, 2017
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosisTarik Asselah, Stefan Bourgeois, Stephen Pianko, et al.
Journal of Hepatology|June 11, 2018
Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipientsKosh Agarwal, Lluís Castells, Beat Müllhaupt, et al.
Journal of Lipid Research|July 14, 2022
Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patientsEric J Lawitz, Kelvin W Li, Edna Nyangau, et al.
Journal of Hepatology|December 3, 2014
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infectionKosh Agarwal, Scott K Fung, Tuan T Nguyen, et al.
Annals of Internal Medicine|November 4, 2014
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot studyAnu Osinusi, Anita Kohli, Miriam M Marti, et al.
Gastroenterology|August 7, 2015
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infectionGraham R Foster, Stephen Pianko, Ashley Brown, et al.
The New England Journal of Medicine|July 10, 2009
Raxibacumab for the treatment of inhalational anthraxThi-Sau Migone, G Mani Subramanian, John Zhong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2016
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL TrialsJason Grebely, Gregory J Dore, Stefan Zeuzem, et al.
Pageof 17